Prioritizing biologically motivated approaches in Mendelian randomization studies

FHS
March 2, 2024
4:38 am

Mendelian randomization, a powerful tool in medical research, helps us understand whether certain factors truly cause disease.

(Favezelimab + pembrolizumab) by Merck for Small-Cell Lung Cancer: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 6, 2023

Magazine: Pharma’s path to Net Zero: Targeting Scope 3 emissions – Pharmaceutical Technology

Share this article In this year’s first issue, we take the opportunity to look back at major drug approvals and regulatory news to size up

January 2, 2024

Why Stoke Therapeutics’ Dravet syndrome drug is worth watching

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Stoke Therapeutics is

December 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.